magicmine/iStock via Getty Images The U.S. FDA has granted accelerated approval to Eli Lilly's ( NYSE: LLY ) Retevmo (Selpercatinib) for pediatric patients two and older for thyroid cancer.
The drug was already approved for patients 12 years and older for thyroid cancer with a type of genetic mutation or gene fusion. Lilly reported Retevmo sales of $253.6M in 2023.
More on Eli Lilly Eli Lilly: Addressing Supply Challenges Should Accelerate Growth Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety Ro provides supply tracking feature for Lilly, Novo Nordisk weight loss drugs SA Asks: Who will launch the next big weight-loss drug?.
